This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EGT-101

Esteve, S.A.

Drug Names(s): AAV Sanfilippo IIIA, adeno-associated virus vector serotype 9 expressing human sulfamidase, MPS IIIA Gene Therapy (Esteve), EGT101, EGT 101

Description: Esteve is developing a novel gene therapy treatment, based on an adeno-associated virus (AAV) vector containing the human sulfamidase gene (AAV-sulfamidase), for Sanfilippo syndrome type A (caused by the lack of heparan N-sulfatase or sulfamidase). AAV-sulfamidase is a genetically modified viral vector derived from a wild-type AAV, a non-pathogenic virus. The recombinant vector has been designed to maximise the sulfamidase therapeutic transgene expression.

Deal Structure: The project Sanfilippo is developed under a Public-Private Partnership (PPP) between Esteve and the UAB (Universitat Autnoma de Barcelona) for the development of gene therapies for mucopolysaccharidosis.


EGT-101 News

Pink Sheet In Brief


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug